Overview

Effect of Dupilumab on Aspirin Intolerance

Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
To test the efficacy of dupilumab in patients with AERD regarding the intolerance to salicylic acid after 6 months. This will be evaluated by oral drug provocation testing with low dose salicylic acid after 6 months of dupilumab treatment. Hypothesis: After 6 months of therapy, patients will tolerate aspirin dose levels as tested with different dosages (125mg, 250mg and 500 mg).
Phase:
Phase 4
Details
Lead Sponsor:
Medical University of Vienna
Treatments:
Aspirin